Kim Ayoung, Mo Kyumin, Kwon Hyeonseok, Choe Soohyun, Park Misung, Kwak Woori, Yoon Hyunho
Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Epigenomes. 2023 Feb 18;7(1):6. doi: 10.3390/epigenomes7010006.
Breast cancer remains a common cause of cancer-related death in women. Therefore, further studies are necessary for the comprehension of breast cancer and the revolution of breast cancer treatment. Cancer is a heterogeneous disease that results from epigenetic alterations in normal cells. Aberrant epigenetic regulation is strongly associated with the development of breast cancer. Current therapeutic approaches target epigenetic alterations rather than genetic mutations due to their reversibility. The formation and maintenance of epigenetic changes depend on specific enzymes, including DNA methyltransferases and histone deacetylases, which are promising targets for epigenetic-based therapy. Epidrugs target different epigenetic alterations, including DNA methylation, histone acetylation, and histone methylation, which can restore normal cellular memory in cancerous diseases. Epigenetic-targeted therapy using epidrugs has anti-tumor effects on malignancies, including breast cancer. This review focuses on the importance of epigenetic regulation and the clinical implications of epidrugs in breast cancer.
乳腺癌仍然是女性癌症相关死亡的常见原因。因此，有必要进行进一步研究以深入了解乳腺癌并推动乳腺癌治疗的变革。癌症是一种异质性疾病，由正常细胞的表观遗传改变引起。异常的表观遗传调控与乳腺癌的发生密切相关。由于表观遗传改变具有可逆性，目前的治疗方法针对的是表观遗传改变而非基因突变。表观遗传变化的形成和维持依赖于特定的酶，包括DNA甲基转移酶和组蛋白去乙酰化酶，这些酶是基于表观遗传学治疗的有前景的靶点。表观遗传药物靶向不同的表观遗传改变，包括DNA甲基化、组蛋白乙酰化和组蛋白甲基化，这些改变可在癌症疾病中恢复正常的细胞记忆。使用表观遗传药物进行的表观遗传靶向治疗对包括乳腺癌在内的恶性肿瘤具有抗肿瘤作用。本综述重点关注表观遗传调控的重要性以及表观遗传药物在乳腺癌中的临床意义。
